John T Lucas1, Adrian M Nida2, Scott Isom3, Kopriva Marshall4, John D Bourland5, Adrian W Laxton6, Stephen B Tatter6, Michael D Chan5. 1. Department of Radiation Oncology, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina. Electronic address: johnthomas75@gmail.com. 2. Biomedical Informatics Center, Medical University of South Carolina, Charleston, South Carolina. 3. Department of Biostatistical Sciences, Section of Biostatistics, Wake Forest School of Medicine, Winston-Salem, North Carolina. 4. Wake Forest School of Medicine, Winston-Salem, North Carolina. 5. Department of Radiation Oncology, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina. 6. Department of Neurosurgery, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina.
Abstract
PURPOSE: To determine factors associated with the durability of stereotactic radiation surgery (SRS) for treatment of trigeminal neuralgia (TN). METHODS AND MATERIALS: Between 1999 and 2008, 446 of 777 patients with TN underwent SRS and had evaluable follow-up in our electronic medical records and phone interview records. The median follow-up was 21.2 months. The Barrow Neurologic Institute (BNI) pain scale was used to determine pre- and post-SRS pain. Dose-volume anatomical measurements, Burchiel pain subtype, pain quality, prior procedures, and medication usage were included in this retrospective cohort to identify factors impacting the time to BNI 4-5 pain relapse by using Cox proportional hazard regression. An internet-based nomogram was constructed based on predictive factors of durable relief pre- and posttreatment at 6-month intervals. RESULTS: Rates of freedom from BNI 4-5 failure at 1, 3, and 5 years were 84.5%, 70.4%, and 46.9%, respectively. Pain relief was BNI 1-3 at 1, 3, and 5 years in 86.1%, 74.3%, and 51.3% of type 1 patients; 79.3%, 46.2%, and 29.3% of type 2 patients; and 62.7%, 50.2%, and 25% of atypical facial pain patients. BNI type 1 pain score was achieved at 1, 3, and 5 years in 62.9%, 43.5%, and 22.0% of patients with type 1 pain and in 47.5%, 25.2%, and 9.2% of type 2 patients, respectively. Only 13% of patients with atypical facial pain achieved BNI 1 response; 42% of patients developed post-Gamma Knife radiation surgery (GKRS) trigeminal dysfunction. Multivariate analysis revealed that post-SRS numbness (hazard ratio [HR], 0.47; P<.0001), type 1 (vs type 2) TN (HR, 0.6; P=.02), and improved post-SRS BNI score at 6 months (HR, 0.009; P<.0001) were predictive of a durable pain response. CONCLUSIONS: The durability of SRS for TN depends on the presenting Burchiel pain type, the post-SRS BNI score, and the presence of post-SRS facial numbness. The durability of pain relief can be estimated pre- and posttreatment by using our nomogram for situations when the potential of relapse may guide the decision for initial intervention.
PURPOSE: To determine factors associated with the durability of stereotactic radiation surgery (SRS) for treatment of trigeminal neuralgia (TN). METHODS AND MATERIALS: Between 1999 and 2008, 446 of 777 patients with TN underwent SRS and had evaluable follow-up in our electronic medical records and phone interview records. The median follow-up was 21.2 months. The Barrow Neurologic Institute (BNI) pain scale was used to determine pre- and post-SRS pain. Dose-volume anatomical measurements, Burchiel pain subtype, pain quality, prior procedures, and medication usage were included in this retrospective cohort to identify factors impacting the time to BNI 4-5 pain relapse by using Cox proportional hazard regression. An internet-based nomogram was constructed based on predictive factors of durable relief pre- and posttreatment at 6-month intervals. RESULTS: Rates of freedom from BNI 4-5 failure at 1, 3, and 5 years were 84.5%, 70.4%, and 46.9%, respectively. Pain relief was BNI 1-3 at 1, 3, and 5 years in 86.1%, 74.3%, and 51.3% of type 1 patients; 79.3%, 46.2%, and 29.3% of type 2 patients; and 62.7%, 50.2%, and 25% of atypical facial painpatients. BNI type 1 pain score was achieved at 1, 3, and 5 years in 62.9%, 43.5%, and 22.0% of patients with type 1 pain and in 47.5%, 25.2%, and 9.2% of type 2 patients, respectively. Only 13% of patients with atypical facial pain achieved BNI 1 response; 42% of patients developed post-Gamma Knife radiation surgery (GKRS) trigeminal dysfunction. Multivariate analysis revealed that post-SRS numbness (hazard ratio [HR], 0.47; P<.0001), type 1 (vs type 2) TN (HR, 0.6; P=.02), and improved post-SRS BNI score at 6 months (HR, 0.009; P<.0001) were predictive of a durable pain response. CONCLUSIONS: The durability of SRS for TN depends on the presenting Burchiel pain type, the post-SRS BNI score, and the presence of post-SRS facial numbness. The durability of pain relief can be estimated pre- and posttreatment by using our nomogram for situations when the potential of relapse may guide the decision for initial intervention.
Authors: Elizabeth C Tyler-Kabara; Amin B Kassam; Michael H Horowitz; Louise Urgo; Constantinos Hadjipanayis; Elad I Levy; Yue-Fang Chang Journal: J Neurosurg Date: 2002-03 Impact factor: 5.115
Authors: Kopriva Marshall; Michael D Chan; Thomas P McCoy; Adam C Aubuchon; J Daniel Bourland; Kevin P McMullen; Allan F deGuzman; Michael T Munley; Edward G Shaw; Stephen B Tatter; Thomas L Ellis Journal: Neurosurgery Date: 2012-03 Impact factor: 4.654
Authors: C L Rogers; A G Shetter; J A Fiedler; K A Smith; P P Han; B L Speiser Journal: Int J Radiat Oncol Biol Phys Date: 2000-07-01 Impact factor: 7.038
Authors: Ron I Riesenburger; Steven W Hwang; Clemens M Schirmer; Vasilios Zerris; Julian K Wu; Kerry Mahn; Paul Klimo; John Mignano; Clinton J Thompson; Kevin C Yao Journal: J Neurosurg Date: 2010-04 Impact factor: 5.115
Authors: D Kondziolka; L D Lunsford; J C Flickinger; R F Young; S Vermeulen; C M Duma; D B Jacques; R W Rand; J Regis; J C Peragut; L Manera; M H Epstein; C Lindquist Journal: J Neurosurg Date: 1996-06 Impact factor: 5.115
Authors: Anil Dhople; Young Kwok; Lawrence Chin; David Shepard; Robert Slawson; Pradip Amin; William Regine Journal: Int J Radiat Oncol Biol Phys Date: 2007-04-30 Impact factor: 7.038
Authors: John R Adler; Regina Bower; Gaurav Gupta; Michael Lim; Allen Efron; Iris C Gibbs; Steven D Chang; Scott G Soltys Journal: Neurosurgery Date: 2009-02 Impact factor: 4.654
Authors: Marcello Marchetti; Valentina Pinzi; Elena De Martin; Francesco Ghielmetti; Laura Fariselli Journal: Neurol Sci Date: 2019-05 Impact factor: 3.307
Authors: Aldo Berti; George Ibars; Xiaodong Wu; Alex Sabo; Michelle Granville; Gail Suarez; James G Schwade; Robert E Jacobson Journal: Cureus Date: 2018-05-09
Authors: Corbin A Helis; Emory McTyre; Michael T Munley; J Daniel Bourland; John T Lucas; Christina K Cramer; Stephen B Tatter; Adrian W Laxton; Michael D Chan Journal: Neurosurgery Date: 2019-11-01 Impact factor: 4.654
Authors: Ellen F Eaton; Ashutosh R Tamhane; Greer A Burkholder; James H Willig; Michael S Saag; Michael J Mugavero Journal: Open Forum Infect Dis Date: 2016-06-16 Impact factor: 3.835
Authors: Lisa B E Shields; Todd S Shanks; Andrew J Shearer; Lauren A Shelton; Brent J Shelton; Jonathan Howe; James M Coons; Brian Plato; Aaron C Spalding Journal: Surg Neurol Int Date: 2017-05-26
Authors: Sana D Karam; Alexander Tai; James W Snider; Shilpa Bhatia; Edward J Bedrick; Abdul Rashid; Ann Jay; Christopher Kalhorn; Nathan Nair; K William Harter; Sean P Collins; Walter Jean Journal: Radiat Oncol Date: 2014-12-14 Impact factor: 3.481